These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34692980)

  • 1. The global Alzheimer's Association round robin study on plasma amyloid β methods.
    Pannee J; Shaw LM; Korecka M; Waligorska T; Teunissen CE; Stoops E; Vanderstichele HMJ; Mauroo K; Verberk IMW; Keshavan A; Pesini P; Sarasa L; Pascual-Lucas M; Fandos N; Allué JA; Portelius E; Andreasson U; Yoda R; Nakamura A; Kaneko N; Yang SY; Liu HC; Palme S; Bittner T; Mawuenyega KG; Ovod V; Bollinger J; Bateman RJ; Li Y; Dage JL; Stomrud E; Hansson O; Schott JM; Blennow K; Zetterberg H
    Alzheimers Dement (Amst); 2021; 13(1):e12242. PubMed ID: 34692980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
    Bali D; Hansson O; Janelidze S
    Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of kidney function and CSF/serum albumin ratio on plasma Aβ42 and Aβ40 levels measured on a fully automated platform in patients with Alzheimer's disease.
    Verde F; Milone I; Dubini A; Colombrita C; Perego A; Solca F; Maranzano A; Ciusani E; Poletti B; Ratti A; Torresani E; Silani V; Ticozzi N
    Neurol Sci; 2023 Sep; 44(9):3287-3290. PubMed ID: 37284933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
    Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jönsson L; Middleton L
    J Prev Alzheimers Dis; 2022; 9(1):12-21. PubMed ID: 35098969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
    Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M;
    Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App
    Andersson E; Schultz N; Saito T; Saido TC; Blennow K; Gouras GK; Zetterberg H; Hansson O
    Alzheimers Res Ther; 2023 Mar; 15(1):64. PubMed ID: 36964585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Correlation Study between Plasma Aβ Proteins and Cerebrospinal Fluid Alzheimer's Disease Biomarkers.
    Shin HS; Lee SK; Kim S; Kim HJ; Chae WS; Park SA
    Dement Neurocogn Disord; 2016 Dec; 15(4):122-128. PubMed ID: 30906353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer's disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study.
    Motta C; Di Donna MG; Bonomi CG; Assogna M; Chiaravalloti A; Mercuri NB; Koch G; Martorana A
    Alzheimers Res Ther; 2023 Aug; 15(1):144. PubMed ID: 37649105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40.
    Wisch JK; Gordon BA; Boerwinkle AH; Luckett PH; Bollinger JG; Ovod V; Li Y; Henson RL; West T; Meyer MR; Kirmess KM; Benzinger TLS; Fagan AM; Morris JC; Bateman RJ; Ances BM; Schindler SE
    Alzheimers Dement (Amst); 2023; 15(1):e12405. PubMed ID: 36874595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
    Blennow K; De Meyer G; Hansson O; Minthon L; Wallin A; Zetterberg H; Lewczuk P; Vanderstichele H; Vanmechelen E; Kornhuber J; Wiltfang J; ; Heuser I; Maier W; Luckhaus C; Rüther E; Hüll M; Jahn H; Gertz HJ; Frölich L; Hampel H; Pernetzki R
    J Nutr Health Aging; 2009 Mar; 13(3):205-8. PubMed ID: 19262954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
    Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
    J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
    Kurz C; Stöckl L; Schrurs I; Suridjan I; Gürsel SÜ; Bittner T; Jethwa A; Perneczky R
    J Neurochem; 2023 Apr; 165(1):95-105. PubMed ID: 36625424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of β-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
    Cai Y; Shi D; Lan G; Chen L; Jiang Y; Zhou L; Guo T;
    Neurology; 2024 Apr; 102(7):e209205. PubMed ID: 38489560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.
    Kim HJ; Park KW; Kim TE; Im JY; Shin HS; Kim S; Lee DH; Ye BS; Kim JH; Kim EJ; Park KH; Han HJ; Jeong JH; Choi SH; Park SA
    J Alzheimers Dis; 2015; 48(4):1043-50. PubMed ID: 26444752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness.
    Shoji M; Kanai M
    J Alzheimers Dis; 2001 Jan; 3(3):313-21. PubMed ID: 22387626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplex immunoassay measurement of amyloid-β
    Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
    Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.